Board of Directors
Education: M.D. 1986 Lund University, Ph.D. 1991 Lund University, Professor 2019 University of Gothenburg.
Experience and prior assignments: Professor Bertil Lindmark has a long and successful career in bio pharma with leading global roles in AstraZeneca and Almirall as well as in several biotech companies. His focus in respiratory, immunology and cancer has led to global drug approvals and successful launches. He has also been involved in several IPOs, major funding events and acquisitions.
Other current assignments: Chief Medical Officer of Galecto Inc., non-executive board member of ALK-Abelló A/S.
Education: Medical degree 1981 at Lund University, Specialist in General Surgery 1987, Professor of Surgery at the School of Medicine, Lund University in 2000.
Experience and prior assignments: Professor Andersson’s clinical work and research focuses on malignancies of the pancreas, liver and biliary tract. He also leads a translational research group with a focus on development of novel biomarker panels for diagnosis, prognosis, assessment, treatment selection and outcomes, as well as on increasing knowledge of the disease itself. He has published about 500 original articles, reviewed articles and book chapters, and supervised 30 Ph.D. students. He also has an extensive international network and has founded six companies in his role as an entrepreneur.
Other current assignments: Chairman of the Board of Reccan Diagnostics AB, Nordic Biotechnology AB and Board member of Lumito AB.
Holdings: 6,434 shares.
Education: Bachelor of laws degree. Served in Stockholm District Court.
Experience and prior assignments: Marie Lidgard has more than 30 years of experience in the financial sector, i. e. as CEO of the Swedish Investment Fund Association. In recent years, she has been active as an investor and founder of several new companies and currently she sits on the Board of Directors for several companies.
Other current assignments: Senior partner at Lavindia AB. Chairman of Fundrella AB. Board member of Von Euler & Partners Kapitalförvaltning AB, Hypoteket Fondförvaltning AB, KONSTAB Film och teater AB, Dreams Securities AB, MoM Lidgard AB and Lavindia AB.
Holdings: 21,715 shares through company.
Education: B.Sc., Business Administration, Lund University 1992.
Experience and prior assignments: Martin Olovsson is CEO of OnDosis, a medtech/healthtech company which he co-founded in 2017. Before this, Martin acquired many years of managerial experience in the pharmaceutical industry with responsibility for portfolio and product strategies, life cycle management, bridging functions such as science and marketing and ensuring commercial excellence. Martin has extensive experience from in- and out-licensing of both pharmaceuticals and technologies. Between 1992 and 2017 he held several international positions within AstraZeneca, including President of the Nordic/Baltic marketing company and Global Vice President of Inhaled Respiratory franchise.
Other current assignments: CEO of OnDosis. Board member of WntResearch AB and IP Enabler AB.
Holdings: 1,500 shares.
Education: Executive MBA, EFL (Executive Foundation Lund), as well as studies in marketing and communication at Lund University.
Experience and prior assignments: Gunilla Savring has many years of experience from leading positions in management and investor relations at development and growth companies such as Axis Communications, Precise Biometrics and Clinical Laserthermia Systems within the IT, pharmaceutical and chemical technology sector. She has also experience from serving on the board of several listed companies.
Other current assignments: CEO and senior consultant in her own company. Board member of aXichem AB and Incendia AB.
Education: M.Sc. in Biotechnology and Biomaterials, Royal Institute of Technology (KTH), 1984; M.B.A. Uppsala University 1992.
Experience and prior assignments: Andreas Segerros has spent most of his career with global pharmaceutical companies. He has many years of experience from international executive positions at Pharmacia Corporation, Pharmacia & Upjohn and Ferring in research & development, marketing and business development in the US, Europe and Japan. He also has experience as a venture capitalist while working as a venture partner and partner at Sunstone Capital. He has made numerous investments in successful growth companies in the life science sector.
Other current assignments: Active as one of the founders of Eir Ventures Partners AB. Chairman of the Board of Oncorena Holding AB and Oncorena AB, Board member of Eir Ventures Partners AB and Merigen AB.